Providence Sacred Heart Medical Center & Children's Hospital
Spokane, Washington, 99204, United States
NCT Number: NCT01459770
Transitional care strategies focused on enhancing the accuracy and comprehensiveness of medication information transfer will lead to improved health outcomes among hospitalized patients with chronic kidney disease.
Looking for future studies?
Notify Me21 year and older
All sexes
Interventional
Not applicable
Spokane, Washington, 99204, United States
Patients with CKD and ESRD have more co-morbidities, are hospitalized more often and for longer lengths of stay, and incur greater healthcare costs than patients with other chronic conditions. Enhanced hospital to home transitional care interventions have been shown to improve medication information transfer, reduce hospital readmissions, and slow the progression of declining health in the general population of hospitalized patients. What is not known is the impact enhanced transitional care can have for a very high-risk population, such as those with CKD and ESRD. Interventions that prevent or slow CKD progression, i.e. blood pressure control and intensive glycemic control in patients with diabetes, are all highly dependent on meticulous medication management.
For hospitalized patients with CKD or ESRD who are transitioning to home, accurate and comprehensive information transfer is essential to optimal medication management. CKD and ESRD patients are in critical need of improved transitional care that includes accurate and comprehensive medication information transfer. The main objective of this application is to pilot-test the effectiveness of a medication information transfer intervention to improve clinically-relevant outcomes. To this end, the following Specific Aims will be achieved: 1. Evaluate the impact of transitional care interventions on acute care utilization following hospital discharge among patients with CKD or ESRD. 2. Evaluate the impact of transitional care strategies on management of CKD or ESRD management and complications.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for CKD arm:
Inclusion criteria
for ESRD arm:
Exclusion criteria
A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.
Patients will receive medication information according to standard practice for discharge of hospitalized patients.
Time frame: 90 days
Acute care utilization defined by emergency department visits and hospitalizations in the first 30 and 90 days after discharge from the index hospitalization.
Time frame: 30 and 90 days
blood pressure, eGFR, urine albumin/creatinine ratio, fasting glucose, HbA1c (in the diabetic subgroup), lipids, hemoglobin, phosphorus, PTH, serum potassium.
Time frame: 30 and 90 days
blood pressure, fasting glucose,HbA1c (in the diabetic subgroup), lipids, hemoglobin, phosphorus, PTH, serum potassium
Providence Medical Research Center
Other
Medication Intervention in Transitional Care to Optimize Outcomes & Costs in CKD & ESRD
Acronym: CKD/ESRD-MIT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03354910
Chronic Disease, Chronic Kidney Disease
Boston, Massachusetts, United States
View Trial DetailsNCT02976220
Chronic Disease, Chronic Kidney Disease
San Francisco, California, United States
View Trial DetailsNCT01786525
Chronic Disease, Chronic Kidney Disease
Boston, Massachusetts, United States
View Trial DetailsNCT00785265
Chronic Disease, Chronic Kidney Disease
Boston, Massachusetts, United States
View Trial Details